First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC

被引：2
|
作者：
Ricciuti, Biagio [1 ]
Chiari, Rita [1 ]
机构：
[1] Univ Perugia, Santa Maria Misericordia Hosp, Dept Med Oncol, Perugia, Italy
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2018年 / 7卷
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; AZD9291;
D O I：
10.21037/tlcr.2018.03.06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S127 / S130
页数：4
相关论文
共 50 条
  • [21] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers Reply
    Schoenfeld, Adam J.
    Yu, Helena A.
    [J]. JAMA ONCOLOGY, 2020, 6 (12) : 1983 - 1983
  • [22] Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
    Ye, Qiuyue
    Xu, Yan
    Zhao, Jing
    Gao, Xiaoxing
    Chen, Minjiang
    Pan, Ruili
    Zhong, Wei
    Wang, Mengzhao
    [J]. TRANSLATIONAL ONCOLOGY, 2023, 31
  • [23] Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics
    de Garibay, G. Ruiz
    Roch, B.
    Garrido Lopez, P.
    Isla, D.
    Aguado, C.
    Callejo Perez, A.
    Marse Fabregat, R.
    Garcia Campelo, M. R.
    Blasco Cordellat, A.
    Sanchez Torres, J. M.
    Bernabe Caro, R.
    Juan Vidal, O. J.
    Carpeno, J. De Castro
    Franco, F. F.
    Ramos Garcia, I.
    Gomez Rueda, A.
    Conde Gallego, E.
    Ponce Aix, S.
    Paz-Ares, L.
    Zugazagoitia, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1015 - S1016
  • [24] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
    Stock-Martineau, Sophie
    Shepherd, Frances A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797
  • [25] Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC
    Kian, W.
    Roisman, L. C.
    Dudnik, J.
    Chernomordikov, L.
    Allen, A. M.
    Corn, B.
    Dudnik, E.
    Rosenberg, S. K.
    Zemel, M.
    Lavrenkov, K.
    Peled, N.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S941 - S941
  • [26] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [27] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
    Le, Xiuning
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jinji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kim
    Mazieres, Julien
    Lye Mun Tho
    Hayashi, Hidetoshi
    Nguyen Nhung
    Chia, Puey Ling
    De Marinis, Fillippo
    Raskin, Jo
    Zhou, Qinghua
    Finochhiaro, Giovanna
    Tan, Daniel
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    [J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [28] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    [J]. ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [29] Efficacy of Chemotherapy after First-Line Gefitinib for EGFR-Mutant NSCLC Patients
    Kuwako, Tomohito
    Imai, Hisao
    Masuda, Tomomi
    Miura, Yosuke
    Yoshino, Reiko
    Kaira, Kyoichi
    Shimizu, Kimihiro
    Sunaga, Noriaki
    Tomizawa, Yoshio
    Ishihara, Shinichi
    Mogi, Akira
    Hisada, Takeshi
    Minato, Koichi
    Takise, Atsushi
    Saito, Ryusei
    Yamada, Masanobu
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S646 - S646
  • [30] Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
    Gettinger, Scott
    Hellmann, Matthew D.
    Chow, Laura Q. M.
    Borghaei, Hossein
    Antonia, Scott
    Brahmer, Julie R.
    Goldman, Jonathan W.
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott A.
    Young, Tina C.
    Li, Xuemei
    Geese, William J.
    Rizvi, Naiyer
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1363 - 1372
12345